Deciphering PI3K biology in health and disease

Informations projet

Phd

N° de convention de subvention: 675392

DOI 10.3030/675392

Projet clôturé

Date de signature de la CE 7 Août 2015

Date de début 1 Novembre 2015

Date de fin 31 Octobre 2019

Financé au titre de

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coût total € 3 896 148,12

Contribution de l’UE € 3 896 148,12

Coordonné par

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Spain

Livrables

Other (6)

Research Training Workshop 2

Research Training Workshop

Research Training Workshop 3

Research Training Workshop

Recruitment
Research Training Workshop 4

Research Training Workshop

PhD Completion

Phd Completion

Research Training Workshop 1

Research Training Workshop

Documents, reports (5)

Dissemination and Outreach Plan 1

Dissemination and Outreach Plan

Dissemination and Outreach Plan 2

Dissemination and Outreach Plan

Dissemination and Outreach Plan 3

Dissemination and Outreach Plan

Mid-term review meeting

Meeting with fellows, members of consortium and REA representative to assess the work progress and achievements

Dissemination and Outreach Plan 4

Dissemination and Outreach Plan

Websites, patent fillings, videos etc. (2)

Network Website
Promotional Video

Publications

Peer reviewed articles (5)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

Auteurs: Ana Angulo-Urarte, Pedro Casado, Sandra D. Castillo, Piotr Kobialka, Maria Paraskevi Kotini, Ana M. Figueiredo, Pau Castel, Vinothini Rajeeve, Maria Milà-Guasch, Jaime Millan, Cora Wiesner, Helena Serra, Laia Muixi, Oriol Casanovas, Francesc Viñals, Markus Affolter, Holger Gerhardt, Stephan Huveneers, Heinz-Georg Belting, Pedro R. Cutillas, Mariona Graupera
Publié dans: Nature Communications, Numéro 9/1, 2018, ISSN 2041-1723
Éditeur: Nature Publishing Group
DOI: 10.1038/s41467-018-07172-3

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Auteurs: Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari, Jürgen Mestan, Paul Hebeisen, Petra Hillmann, Bernd Giese, Marketa Zvelebil, Doriano Fabbro, Roger L. Williams, Denise Rageot, Matthias P. Wymann
Publié dans: Journal of Medicinal Chemistry, Numéro 60/17, 2017, Page(s) 7524-7538, ISSN 0022-2623
Éditeur: American Chemical Society
DOI: 10.1021/acs.jmedchem.7b00930

The role of metabolic adaptation to nutrient stress in pancreatic cancer

Auteurs: Abhishek Derle, Maria Chiara De Santis, Luca Gozzelino, Edoardo Ratto, Miriam Martini
Publié dans: Cell Stress, Numéro 2/12, 2018, Page(s) 332-339, ISSN 2523-0204
Éditeur: Shared Science Publishers
DOI: 10.15698/cst2018.12.166

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

Auteurs: Célia Cintas, Thibaut Douché, Nicole Therville, Silvia Arcucci, Fernanda Ramos-Delgado, Céline Basset, Benoît Thibault, Julie Guillermet-Guibert
Publié dans: Cancers, Numéro 10/6, 2018, Page(s) 174, ISSN 2072-6694
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers10060174

Experimental pancreatic cancer develops in soft pancreas: novel leads for an individualized diagnosis by ultrafast elasticity imaging

Auteurs: Nicole Therville, Silvia Arcucci, Aurélie Vertut, Fernanda Ramos-Delgado, Dina Ferreira Da Mota, Marlène Dufresne, Céline Basset, Julie Guillermet-Guibert
Publié dans: Theranostics, Numéro 9/22, 2019, Page(s) 6369-6379, ISSN 1838-7640
Éditeur: Ivyspring International Publisher
DOI: 10.7150/thno.34066